High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: week 48 results in an observational cohort | Zendy

Charlotte Charpentier | Zendy; Gilles Peytavin | Zendy; Minh Patrick Lê | Zendy; Véronique Joly | Zendy; Ornella Cabras | Zendy; Marine Perrier | Zendy; Sylvie Le Gac | Zendy; Bao Phung | Zendy; Yazdan Yazdanpanah | Zendy; Diane Descamps | Zendy; Roland Landman | Zendy

Open Access

High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: week 48 results in an observational cohort

Author(s) -

Charlotte Charpentier,

Gilles Peytavin,

Minh Patrick Lê,

Véronique Joly,

Ornella Cabras,

Marine Perrier,

Sylvie Le Gac,

Bao Phung,

Yazdan Yazdanpanah,

Diane Descamps,

Roland Landman

Publication year - 2018

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dky062

Subject(s) - dolutegravir , regimen , medicine , cohort , adverse effect , viral load , gastroenterology , observational study , human immunodeficiency virus (hiv) , virology , antiretroviral therapy

To assess, in a clinical cohort, the efficacy of switching current ART in virologically suppressed patients to a dolutegravir-based regimen, regardless of the genotypic susceptibility score (GSS).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research